Daunorubicin/cytarabine

Cincinnati Children's Launches Advanced Leukemia Therapies and Research Center

Retrieved on: 
Tuesday, September 26, 2023
University, Life, Education, Health, Bone marrow, The Hospital Research Foundation, Research, Cincinnati Children's Hospital Medical Center, Cell, Doctor of Philosophy, Science, U.S. News & World Report, AML, UC, MD, Patient, Division, Leukemia, FDA, News, Pharmaceutical industry, Nursing, Dentistry, Pediatrics, Daunorubicin/cytarabine, Cancer

CINCINNATI, Sept. 26, 2023 /PRNewswire/ -- Cincinnati Children's, the top ranked pediatric hospital and top ranked cancer program in the country by U.S. News & World Report, continues to break new ground with the launch of the first of its kind Advanced Leukemia Therapies and Research Center. The center will integrate the expertise of the world class research and clinical programs at Cincinnati Children's and increase patient access to cutting edge clinical trials.

Key Points: 
  • "We want to improve the outcomes of Acute Myeloid Leukemia (AML) patients by spearheading innovative and transformative research that will bring new treatment options to blood cancer patients of any age," said Daniel Starczynowski, PhD, director of the Cincinnati Children's Advanced Leukemia Therapies and Research Center, associate director of the Cancer and Blood Diseases Institute and associate director for basic science research at the University of Cincinnati Cancer Center.
  • Cincinnati Children's formed the Advanced Leukemia Therapies and Research Center to accelerate more scientific discoveries like this to bring more curative options to AML patients.
  • The addition of the Advanced Leukemia Therapies and Research Center further confirms Cincinnati Children's as a global leader in cancer care, research and education.
  • "The Advanced Leukemia Therapies and Research Center and the progress we are making there sets Cincinnati Children's apart from other pediatric academic research centers."

Global Nanoparticle Formulation Market Report 2023: Rising Interest in Nanoparticle-based Vaccines to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 5, 2023
Health, Pharmaceutical, Vaccine, Dentistry, Acuitas Therapeutics, Nanoparticle, Nano, Therapy, Coronavirus, Administration, European Medicines Agency, Cancer, DSM-IV codes, Bone marrow, Emergent, Infection, Research, Messenger, Acute myeloid leukemia, EMA, CDMO, Permeability, Jazz Pharmaceuticals, Merck, LNP, Pfizer, Environmental remediation, Pharmaceutical industry, Daunorubicin/cytarabine, Fujifilm

The global nanoparticle formulation market was estimated to be worth USD 5.1 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 9.4% during the forecast period.

Key Points: 
  • The global nanoparticle formulation market was estimated to be worth USD 5.1 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 9.4% during the forecast period.
  • This report features an extensive study of the current market landscape, market size and future opportunities associated with the nanoparticle formulation technologies and services market, during the given forecast period.
  • The nanoparticles need to be engineered through advanced nanoparticle formulation and nanoparticle manufacturing techniques that require specialized technical expertise.
  • Further, driven by the growing demand for nanoparticle-based therapeutics, the nanoparticle formulation market is anticipated to witness substantial growth during the forecast period.

GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs

Retrieved on: 
Monday, November 22, 2021
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cell, Risk, Breakthrough therapy, Forward-looking statement, Biology, AML, Cancer, CXCR4, Acute myeloid leukemia, SEC, University of Michigan, University, Annual report, Daunorubicin/cytarabine, U.S. Securities and Exchange Commission, Nasdaq, Adult, E-selectin, NDA, Hematology, Eastern Michigan University, FDA, Bone marrow, Form 10-K, Drug development, Food, Regulatory affairs, Pharmaceutical industry, Uproleselan (GMI-1271), GlycoMimetics, Inc., UPROLESELAN (GMI-1271), GLYCOMIMETICS, INC.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Lisa DeLuca, Ph.D., has joined its executive leadership team as Vice President, Regulatory Affairs.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Lisa DeLuca, Ph.D., has joined its executive leadership team as Vice President, Regulatory Affairs.
  • Dr. DeLuca is a veteran regulatory expert who has previously led the strategy-formation and execution of multiple global NDA submissions and product registrations.
  • Most recently she was the head of regulatory affairs at Nuvation Bio and a member of its executive leadership team.
  • Lisa is a seasoned executive who brings to GlycoMimetics significant expertise in regulatory strategy and agency interactions.

Cleave Therapeutics Announces Preclinical Research Collaboration With Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)

Retrieved on: 
Wednesday, September 9, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Drugs, RTT, Clinical medicine, Daunorubicin/cytarabine, Acute myeloid leukemia, Daunorubicin, Jazz Pharmaceuticals, Oncology, 7+3, Cytarabine, Vyxeos® (daunorubicin and cytarabine), Cleave Therapeutics and CB-5339

Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in oncology, announced that it has entered into a preclinical research collaboration with Jazz Pharmaceuticals, a global biopharmaceutical company developing life-changing medicines for people with serious diseases.

Key Points: 
  • Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in oncology, announced that it has entered into a preclinical research collaboration with Jazz Pharmaceuticals, a global biopharmaceutical company developing life-changing medicines for people with serious diseases.
  • CB-5339 plays a key role in DNA damage repair and has demonstrated impressive preclinical activity and synergy in combination with DNA-damaging agents.
  • In Europe, Vyxeos Liposomal (daunorubicin/cytarabine) is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
  • Cleave Therapeutics is a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer.

Tolero Pharmaceuticals to Highlight Clinical Data Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed AML at EHA 2019

Retrieved on: 
Thursday, May 16, 2019
Drugs, Chemical compounds, Organic compounds, Lactams, RTT, Orphan drugs, Protein kinase inhibitors, Chromones, Myelodysplastic syndrome, Decitabine, 7+3, Daunorubicin/cytarabine

Alvocidib is also being evaluated in Zella 101, a Phase I clinical study evaluating the maximum tolerated dose, safety and clinical activity of alvocidib in combination with cytarabine/daunorubicin(7+3) in newly diagnosed patients with AML ( NCT03298984 ), and Zella 102, a Phase 1b/2 study in patients with myelodysplastic syndromes (MDS) in combination with decitabine ( NCT03593915 ).

Key Points: 
  • Alvocidib is also being evaluated in Zella 101, a Phase I clinical study evaluating the maximum tolerated dose, safety and clinical activity of alvocidib in combination with cytarabine/daunorubicin(7+3) in newly diagnosed patients with AML ( NCT03298984 ), and Zella 102, a Phase 1b/2 study in patients with myelodysplastic syndromes (MDS) in combination with decitabine ( NCT03593915 ).
  • In addition, alvocidib is being evaluated in a Phase 1 study in patients with relapsed or refractory AML in combination with venetoclax ( NCT03441555 ).
  • Tolero Pharmaceuticals is based in the United States and is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan.
  • Any forward-looking statements set forth in this press release speak only as of the date of this press release.